Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rexahn Pharmaceuticals (REXN)

Rexahn Pharmaceuticals (REXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,115
  • Shares Outstanding, K 4,483
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,640 K
  • 60-Month Beta 1.08
  • Price/Sales 7.06
  • Price/Cash Flow N/A
  • Price/Book 1.42
Trade REXN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.26
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 11/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7200 +5.23%
on 11/05/20
2.3850 -24.11%
on 10/20/20
-0.2900 (-13.81%)
since 10/05/20
3-Month
1.6969 +6.67%
on 09/16/20
2.7163 -33.37%
on 08/11/20
-0.7700 (-29.84%)
since 08/05/20
52-Week
1.2626 +43.35%
on 03/19/20
4.2600 -57.51%
on 02/11/20
-0.2400 (-11.71%)
since 11/05/19

Most Recent Stories

More News
Ocuphire to Participate in Upcoming Virtual HCW Conference in November

FARMINGTON HILLS, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment...

REXN : 7.2400 (-3.21%)
OCUP : 2.01 (-0.50%)
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP

Merger completed with Rexahn Pharmace u ticals c reat ing a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates

REXN : 7.2400 (-3.21%)
Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected...

REXN : 7.2400 (-3.21%)
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma

ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn’s...

REXN : 7.2400 (-3.21%)
SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Mergers; Shareholders are Encouraged to Contact the Firm – MJCO, REXN, NTN, SUNW

NEW YORK, NY / ACCESSWIRE / August 22, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Majesco (NASDAQ:MJCO) concerning potential violations of the federal securities laws...

MJCO : 16.00 (+0.19%)
REXN : 7.2400 (-3.21%)
NTN : 5.40 (+1.12%)
SUNW : 0.0600 (-40.48%)
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - REXN, DCOM, NGHC, INWK

NEW YORK, NY / ACCESSWIRE / July 25, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) concerning potential violations of the federal...

ALL : 173.01 (+1.87%)
REXN : 7.2400 (-3.21%)
DCOM : 19.26 (-0.16%)
NGHC : 34.18 (+0.09%)
INWK : 2.99 (-0.17%)
SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MXIM, BFYT, ADSW, REXN

SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MXIM, BFYT, ADSW, REXN NEW YORK, NY / ACCESSWIRE...

MXIM : 103.14 (-1.18%)
BFYT : 31.00 (+0.10%)
ADSW : 30.30 (+0.03%)
REXN : 7.2400 (-3.21%)
Lifshitz Law Firm, P.C. Announces Investigation of Benefytt Technologies, Inc., Noble Energy, Inc., Maxim Integrated Products and Rexahn Pharmaceuticals, Inc.

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) --

BFYT : 31.00 (+0.10%)
MXIM : 103.14 (-1.18%)
REXN : 7.2400 (-3.21%)
NBL : 8.46 (+1.44%)
ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - ADI, GRUB, REXN

NEW YORK, NY / ACCESSWIRE / July 18, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased...

ADI : 197.79 (+2.31%)
GRUB : 6.72 (+10.71%)
REXN : 7.2400 (-3.21%)
INVESTIGATION ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - GARS, NVTA, REXN

NEW YORK, NY / ACCESSWIRE / July 14, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased...

GARS : 3.88 (-1.65%)
NVTA : 0.0195 (+2.63%)
REXN : 7.2400 (-3.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 2.0300
1st Resistance Point 1.9200
Last Price 7.2400
1st Support Level 1.7100
2nd Support Level 1.6100
3rd Support Level N/A

See More

Last Price 7.2400
52-Week High 4.2600
Fibonacci 61.8% 3.1150
Fibonacci 50% 2.7613
Fibonacci 38.2% 2.4076
52-Week Low 1.2626

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar